Longeveron (LGVN) announced that the China National Intellectual Property Administration has granted a patent covering potency assay methods for assessing human mesenchymal stem cells derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells. Potency assays are a crucial element for approved cell-based therapy products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron Receives Extended Nasdaq Compliance Grace Period
- Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
- Longeveron’s Alzheimer’s Program Faces High Late-Stage Failure Risk and Potential Pipeline Pressure
- Longeveron Earnings Call: Pivotal Trials, Tight Cash
- Longeveron price target lowered to $2 from $3 at Roth Capital